The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
Public ClinicalTrials.gov record NCT06291415. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523, a Syk Inhibitor, in Adult Subjects With Immune Thrombocytopenia
Study identification
- NCT ID
- NCT06291415
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Hutchmed
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
- Immune Thrombocytopenia
- Blood Platelet Disorder
- Hematologic Diseases
- Purpura, Thrombocytopenic
- Purpura
- Blood Coagulation Disorder
- Thrombotic Microangiopathies
- Hemorrhagic Disorders
- Autoimmune Diseases
- Immune System Diseases
- Hemorrhage
- Pathologic Processes
- Skin Manifestations
- Thrombocytopenia
- Purpura, Thrombocytopenic, Idiopathic
- Primary Immune Thrombocytopenia
- ITP - Immune Thrombocytopenia
Interventions
- HMPL-523 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 1, 2024
- Primary completion
- Mar 31, 2026
- Completion
- Oct 31, 2026
- Last update posted
- Sep 15, 2025
2024 – 2026
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Childrens Hospital of California | Irvine | California | 92868 | — |
| Georgetown University Medical Center - Georgetown Lombardi Comprehensive Cancer Center | Georgetown | Delaware | 20007 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| San Juan Oncology Associates | Farmington | New Mexico | 87401 | — |
| East Carolina University, Brody School of Medicine | Greenville | North Carolina | 27834 | — |
| Taussig Cancer Institute | Cleveland | Ohio | 44106 | — |
| Oklahoma Cancer Specialists and Research Institute | Tulsa | Oklahoma | 74146 | — |
| Texas Oncology San Antonio Medical Center | San Antonio | Texas | 78240 | — |
| University of Washington (UW) Medical Center | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06291415, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 15, 2025 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06291415 live on ClinicalTrials.gov.